Endocrinology and metabolism clinics of North America

Guidelines for Using Glucagon-like Peptide-1 Medicines Safely in Adults with Type 1 Diabetes

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) may provide safe adjunctive therapy in adults with type 1 diabetes (T1D).

  • Certain phenotypes of type 1 diabetes are identified as potentially benefiting from GLP-1RA therapy.
  • Best practices for initiating and adjusting GLP-1RAs are outlined to enhance patient care.
  • Patient education and counseling components are critical for the effective use of GLP-1RAs.
  • Monitoring strategies and methods to reduce adverse effects are detailed for safer use.
  • A practical framework for insulin dose adjustments is proposed to personalize treatment.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Funding

Competing interests

Disclosure Z.I. Saeed’s institution has received research support from Amylyx Pharmaceuticals and Eli Lilly. Z.I. Saeed has received honoraria from Sanofi for consulting. V.N. Shah’s institution has received research support from Dexcom, United States, Minimed, Eli Lilly, Enable Bioscience, Zucara Therapeutics, Cystic Fibrosis Foundation, United States, DEKA Research, Breakthrough T1D, and NIH and V.N. Shah has received honoraria from Sanofi, Lilly, NovoNordisk, Insulet, Dexcom, Tandem Diabetes Care, Sequel Med Tech, Biomea Fusion, Abbott, Minimed, Roche, and T1D Scout for speaking, consulting, or serving on an advisory board.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #48
Stop the drug, regain the weight: pooled data puts the average rebound at 7%
2 days ago7 studies
issue #47
The brain region that explains why blocking and activating the same receptor both cause weight loss
1 week ago7 studies
issue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
2 weeks ago7 studies
issue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
3 weeks ago7 studies
issue #44
Tirzepatide cut all-cause mortality by more than half compared to semaglutide in a 47,000-patient study
4 weeks ago7 studies
issue #43
Semaglutide linked to 21% lower psychiatric hospitalization risk in bipolar disorder patients
5 weeks ago7 studies
issue #42
Tirzepatide users lost 14.7% of body weight vs. 10.8% with semaglutide — but Black and Hispanic patients were overrepresented in the lowest-response group
6 weeks ago8 studies
issue #41
New obesity drug survodutide cut weight by 13% vs 5.4% for placebo in 725 patients
7 weeks ago7 studies
issue #40
GLP-1 users had 3x higher risk of aspiration pneumonia after stroke surgery
8 weeks ago7 studies
issue #39
Semaglutide linked to reduced cigarette craving in 24 smokers
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief